Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study-Reference-Cited by-同舟云学术

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

Published:2015-01-07 Issue:269 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Schweizer Michael T.¹,Antonarakis Emmanuel S.¹,Wang Hao¹,Ajiboye A. Seun¹,Spitz Avery¹,Cao Haiyi¹,Luo Jun¹,Haffner Michael C.¹,Yegnasubramanian Srinivasan¹,Carducci Michael A.¹,Eisenberger Mario A.¹,Isaacs John T.¹,Denmeade Samuel R.¹

Affiliation:

1. The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Abstract

Intermittent treatment with high-dose testosterone shows therapeutic potential in patients with castration-resistant prostate cancer.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference60 articles.

1. Studies on prostatic cancer

2. STUDIES ON PROSTATIC CANCER

3. PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

4. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma

5. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;Nature Genetics;2024-09-09

2. Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling;Radiation Oncology;2024-07-02

3. An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer;Royal Society Open Science;2024-07

4. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain;Oncogene;2024-03-26

5. Canonical AREs are tumor suppressive regulatory elements in the prostate;2024-02-27